5-year Follow-up After a Single Dose Acellular Pertussis Vaccination

January 3, 2022 updated by: Punnee Pitisuttithum, Mahidol University

Antibody Persistence at 5 Years After a Single Dose Vaccination of Acellular Pertussis Vaccines Containing Genetically-inactivated Pertussis Toxin

In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccines) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy participants aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th;Study ID:TCTR20150703002). A total of 450 participants were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 participants enrolled at each study site. During the study, the participants had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines.

This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of participants who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects).

In this current study, the long-term persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-inactivated Tdap vaccine (Adacel) at 5 years after previously immunized in the TDA202 study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study population will included all participants who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok.

Participants from all 3 vaccine groups (i.e., participants who had received a single dose of one of the 3 study vaccines (Boostagen®, Pertagen®, or Adacel®) and completed 1-year follow-up visit at Day 336±28 days during the TDA202 study will be called in for informed consent process at Visit 1 at approximately 5 years after vaccination (±56 days) based on Vaccination Date in the TDA202 study. Participants aged ≥18 years who have signed the written Informed Consent Form or participants aged less than 18 years who have co-signed the Informed Consent Form with their parent/legal will be screened for general health status (a survey for medical history, immunization history, history of receiving blood, blood component, immunoglobulin, immunosuppressive drugs or systemic corticosteroid and physical examination) and those who fulfill the pre-defined inclusion criteria and do not meet an exclusion criteria will be enrolled into the study.

Once enrolled, a blood sample (approx. 5 mL) will be taken from all participants. After blood collection, this will be considered as study end for all participants. Participants will be offered a licensed influenza vaccine at the end of Visit 1.

Blood samples collected from all participants who have come back for the 5-year follow-up visit (Visit 1) will be processed for serum preparation. Serum samples will be stored at the laboratory at the study site and will be further shipped to BioNet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against Pertussis Toxin (PT), Filamentous hemagglutinin (FHA), Diphtheria Toxin (DT), and Tetanus Toxin (TT) and PT-neutralizing antibody by Chinese Hamster Ovary (CHO) cells assay) will be performed. ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled participants while CHO cells assay to detect PT-neutralizing antibody will be performed only in the same subset of participants who had been selected for PT-neutralizing antibody study in the initial TDA202 study.

The knowledge from this long-term 5-year antibody persistence study will provide supportive data to identify the best alternative acellular pertussis vaccines to conventional chemically-inactivated vaccines for controlling the resurgence of pertussis disease.

Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.

Study Type

Observational

Enrollment (Actual)

159

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
      • Bangkok, Thailand, 10400
        • Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi,

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The target population for this study is the group of participants who had received one dose of acellular pertussis based vaccine in TDA202 trial at Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University and who had completed the study follow-up at 1 year after vaccination.

Description

Inclusion Criteria:

A participant will be eligible for inclusion if ALL of the followings apply at the time of screening:

  1. Having participated in the initial TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1-year follow-up visit;
  2. Written informed consent is obtained for participants aged ≥18 years, or written informed consent are obtained from participants aged <18 years with their parents/legal guardians, co-signed prior to study entry;
  3. Healthy, as established by pertinent medical history and physical examination;
  4. Capable of complying with study procedures and willing to provide with a blood sample

Exclusion Criteria:

1. Having received pertussis vaccine since TDA202 study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
acellular pertussis vaccine
Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
Biological: Biological/Vaccine: Pertagen (aP BioNet)

Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Biological: Biological/Vaccine: Boostagen (TdaP BioNet)

Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Biological: Biological/Vaccine: Adacel

Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anti-PT and Anti-FHA GMTs (IU/ml) changed from baseline at 5 Years After Vaccination in All Evaluable Participants by Vaccine Groups
Time Frame: 5 years after vaccination ± 56 days
Anti-PT and anti-FHA GMTs (IU/mL) at baseline and 5 years after vaccination as assess by ELISA in all evaluable participants by vaccine groups.
5 years after vaccination ± 56 days
Anti-Tetanus and Anti-Diphtheria GMTs (IU/mL) changed from baseline at 5 Years After Vaccination in All Evaluable Participants in Boostagen (BioNet TdaP BioNet) and Adacel Vaccine Groups
Time Frame: 5 years after vaccination ± 56 days
Anti-Tetanus and anti-Diphtheria GMTs (IU/mL) between baseline and 5 years after vaccination as assessed by ELISA in all evaluable participants in Boostagen (BioNet TdaP BioNet) and Adacel vaccine groups
5 years after vaccination ± 56 days
Seroconversion Rates as Defined by the Proportion of Participants With Booster Response in Anti-PT and Anti-FHA Antibody Titers at Day 28 and 5 Years After Vaccination Compared to Baseline in All Evaluable Participants by Vaccine Groups
Time Frame: 5 years after vaccination ± 56 days

Booster response:

  • In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL;
  • In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer;
  • In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
5 years after vaccination ± 56 days
PT Neutralizing GMTs (IU/mL) changed from baseline at 5 Year After Vaccination as Assessed in a Subset of Evaluable Participants by Vaccine Group
Time Frame: 5 years after vaccination ± 56 days
PT neutralizing GMTs (IU/mL) between baseline and 5 year after vaccination as assessed by PT neutralizing assay in a subset of evaluable participants by vaccine group
5 years after vaccination ± 56 days
Seroconversion Rates Defined by Proportion of Participants With ≥ 4-fold Changed in PT Neutralizing Antibody Titers at Day 28, Day 336 and 5 Years After Vaccination Compared to Baseline in a Subset of Evaluable Participants
Time Frame: Day 28, Day 336 and 5 years after vaccination ± 56 days
Seroconversion rates as defined by the proportion of participants with ≥ 4-fold increase in PT neutralizing antibody titers at Day 28, Day 336 and 5 years after vaccination compared to baseline as assessed by PT neutralizing assay in a subset of evaluable participants by vaccine group
Day 28, Day 336 and 5 years after vaccination ± 56 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mahidol University

Collaborators

BioNet-Asia Co., Ltd.

Investigators

  • Principal Investigator: Punnee Pitisuttithum, MD, VTC, Faculty of Tropical Medicine, Mahidol University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 24, 2020

Primary Completion (Actual)

September 2, 2020

Study Completion (Actual)

November 3, 2021

Study Registration Dates

First Submitted

August 20, 2020

First Submitted That Met QC Criteria

August 24, 2020

First Posted (Actual)

August 28, 2020

Study Record Updates

Last Update Posted (Actual)

January 5, 2022

Last Update Submitted That Met QC Criteria

January 3, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TDA202 5 year follow-up

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pertussis

Clinical Trials on Biological/Vaccine: Pertagen (aP BioNet)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe